Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?

Dig Liver Dis. 2024 Mar;56(3):530-531. doi: 10.1016/j.dld.2023.11.039. Epub 2023 Dec 8.

Authors

Ilhami Yuksel¹, Yavuz Cagir², Ali Atay²

Affiliations

¹ Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara, Turkey; Department of Gastroenterology, Ankara Yildirim Beyazit University School of Medicine, Ankara, Turkey. Electronic address: yukselilhami@hotmail.com.
² Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara, Turkey.

PMID: 38071183
DOI: 10.1016/j.dld.2023.11.039

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Combined Modality Therapy
Drug Therapy, Combination
Gastrointestinal Agents / therapeutic use
Humans
Immunologic Factors*
Infliximab / therapeutic use
Treatment Outcome

Substances

Infliximab
Immunologic Factors
Antibodies, Monoclonal
Gastrointestinal Agents